Xencor
111 West Lemon Avenue
2nd floor
Monrovia
California
91016
United States
Tel: 626-305-5900
Website: http://www.xencor.com/
269 articles with Xencor
-
Xencor Reports Third Quarter 2018 Financial Results
11/5/2018
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today reported financial results for the third quarter ended September 30, 2018 and provided a review of recent business and clinical highlights.
-
Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting
11/1/2018
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic diseases, and cancer, today announced that initial data from its ongoing Phase 1 dose-escalation study of XmAb®14045, a CD123 x CD3 bispecific antibody, in patients with relapsed/refractory acute myeloid leukemia (AML) will be presented
-
Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018
10/29/2018
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that it will release third quarter 2018 financial results after the market closes on Monday, November 5, 2018.
-
However, because the trial did show some efficacy and met other secondary endpoints, the companies are continuing to analyze the data and decide on their next moves.
-
Xencor to Participate in Upcoming October 2018 Investor Conferences
9/25/2018
Xencor, Inc. today announced that company management will participate in three upcoming conferences:
-
Tarveda Therapeutics Appoints Jeffrey Bloss, M.D. as Chief Medical Officer
9/12/2018
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
-
Xencor Reports Second Quarter 2018 Financial Results
8/6/2018
Dosed the First Patient in DUET-2, Phase 1 Clinical Trial of Lead Tumor Microenvironment (TME) Activator XmAb®20717 in Advanced Solid Tumors
-
Xencor to Present at Upcoming August 2018 Investor Conferences
8/1/2018
Xencor, Inc. announced that company management will present at two upcoming conferences
-
Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018
7/30/2018
Xencor, Inc. announced that it will release second quarter 2018 financial results after the market closes on Monday, August 6, 2018.
-
Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors
7/12/2018
Xencor, Inc. announced that the first patient has been dosed in XmAb20717-01 (DUET-2)
-
Xencor to Present at Two Upcoming Investor Conferences
5/31/2018
Xencor, Inc. announced that company management will present at two upcoming conferences.
-
Xencor Reports First Quarter 2018 Financial Results
5/7/2018
-- Introduced XmAb® IL15 Bispecific Antibody Platform and Presented Preclinical Data on XmAb®24306 at American Association for Cancer Research (AACR) Annual Meeting -- - Completed Public Offering, Raising $245.5M and Extending Cash Runway into 2023 - -- Expect to Initiate Phase 3 Trial of XmAb®5871 in IgG4-Related Disease (IgG4-RD) and to Announce Initial Clinical Data from Two Ongoing Clinical Trials in 2H18 -- - Management to Host Conference Call at 4:30 pm ET today -
-
Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference
5/2/2018
Xencor, Inc. announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will present at the Deutsche Bank 43rd Annual Health Care Conference on Wednesday, May 9, 2018 at 9:20 a.m. ET in Boston, MA.
-
Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018
4/30/2018
Xencor, Inc. announced that it will release first quarter 2018 financial results after the market closes on Monday, May 7, 2018.
-
The 2018 American Association for Cancer Research (AACR) is being held in Chicago. Here’s a roundup of some of today’s company news.
-
Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting
4/18/2018
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, announced preclinical data on XmAb24306, an IL15/IL15-receptor alpha complex fused to a bispecific XmAb Fc domain (IL15/IL15Rα-Fc) for the treatment of multiple oncology indications
-
Applied BioMath, LLC Collaborates with Xencor for Semi-Mechanistic PK/PD Modeling of XmAb®24306, Xencor's Lead IL15 Program for the Treatment of Solid Tumors
4/18/2018
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform semi-mechanistic PK/PD modeling to analyze Xencor's XmAb® IL15/IL15Rα-Fc program for the treatment of solid tumors.
-
Xencor Announces Pricing of Public Offering of Common Stock
3/20/2018
Xencor announced the pricing of an underwritten public offering of 7,300,000 shares of its common stock at a price to the public of $31.00 per share.
-
Xencor, Inc. Announces Proposed Public Offering of Common Stock
3/19/2018
Xencor Inc. announced that it intends to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering.
-
Xencor Reports Fourth Quarter and Full Year 2017 Financial Results
2/27/2018
Xencor, Inc. reported financial results for the fourth quarter and full year ended December 31, 2017 and provided a review of 2017 and recent business and clinical highlights.